IL-5 antagonist monoclonal antibody
This page covers all IL-5 antagonist monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting IL-5 (Interleukin-5).
Targets
Marketed (1)
- Mepolizumab Injection [Nucala] · KU Leuven · Immunology / Respiratory
Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the blood and tissues.
Phase 3 pipeline (4)
- Mepolizumab 100 milligrams · GlaxoSmithKline · Immunology
Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the immune system. - Mepolizumab IV · GlaxoSmithKline · Immunology
Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the immune system. - Mepolizumab SC · GlaxoSmithKline · Immunology
Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the immune system. - Liquid mepolizumab · GlaxoSmithKline · Immunology
Mepolizumab is a monoclonal antibody that binds to interleukin-5 (IL-5) and prevents its interaction with eosinophils, reducing eosinophil production and activation.
Patent intelligence
- il 5 antagonist monoclonal antibody patent landscape — aggregated cliff calendar, attackable patents, originator estates